Approval · Notice of Compliance 35802 · 2025
HEPCLUDEX: Notice of Compliance 35802
Issued August 8, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35802
- Date
- August 8, 2025
- Company
- Gilead Sciences Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HEPCLUDEX | 02560178 | Marketed |
Medicinal ingredients
- BULEVIRTIDE ACETATE 2 MG per VIAL